Friday, August 17, 2018
Company News: Page (1) of 1 - 01/16/18 Email this story to a friend. email article Print this page (Article printing at page facebook
Saniona AB: Saniona initiates Phase I study with new Tesomet tablet

(January 16, 2018)


January 16, 2018

Saniona, a leading biotech company in the field of ion channels, today announced that it has dosed the first 10 participants in a Phase 1 pharmacokinetic study of Tesomet using the new patented single tablet formulation. The trial will comprise a total of 60 volunteers. Saniona expects to report results from the trial in the second quarter 2018.

"We have invested significant time and effort into producing our new patented and GMP validated Tesomet fixed dose combination tablets together with our formulation partner Solural. It is very exciting for us to evaluate this innovative formulation in humans for the first time," commented Jørgen Drejer, CEO of Saniona.

The primary objective of this Phase 1 study is to evaluate the pharmacokinetic profile and bioavailability of a single dose of the Tesomet fixed-dose combination tablet (containing both tesofensine and metoprolol) compared to the co-administration of separate tesofensine and metoprolol tablets.

This is a randomized, open-label, parallel-arm study in 60 healthy male subjects. Each subject will participate in a screening period, a baseline period, and a single-dose treatment period with an on-site observation period of at least 48 hours after the dose. The study is being conducted by Parexel in Germany at their clinical site in Berlin.

Further details about the trial can be found at NCT03286829

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: [email protected]

This information is information that Saniona (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and Sweden's Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 13:20 CET on January 16, 2018. 

About Saniona

Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq Stockholm Small Cap and has about 5,300 shareholders. The company's share is traded under the ticker SANION. Read more at


Page: 1

Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • The Alzheimer's Research and Prevention Foundation (ARPF) Announces Second Brain Longevity® Therapy Training Program in Washington D.C.
  • Image Guided Radiotherapy Market to Experience Unfaltering Growth at 15.8% CAGR to Revolutionize the Healthcare Sector by 2023
  • Disposable Negative Pressure Wound Therapy Devices Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2027)
  • Elysium Health™ Announces Exclusive License for Use of Nicotinamide Riboside for the Slowing of Aging and Prevention of Age-Related Diseases from Mayo Clinic and Harvard

  • Biotest AG: Cytotect(R) CP prevents transmission of Cytomegalovirus (CMV) to the unborn baby in pregnant women who are infected with CMV for the first time
  • ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
  • Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
  • Agenus Receives Second Milestone Payment from Merck
  • Colorado Pain Care Broadens Practice to Include Cancer Patient Treatment in Denver, CO and Surrounding Area

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines